"10.1371_journal.pone.0091398","plos one","2014-03-12T00:00:00Z","Jean-Christophe Lega; Laurent Bertoletti; Cyrielle Gremillet; Céline Chapelle; Patrick Mismetti; Michel Cucherat; Denis Vital-Durand; Silvy Laporte; on behalf of The Meta-Embol Group","Département de Médecine Interne et Vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France; Groupe de Recherche sur la Thrombose, EA3065, Université de Saint-Etienne, Jean Monnet, Saint-Etienne, France; Département de Médecine Thérapeutique, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France; Inserm, CIE3, Saint-Etienne, France; UMR CNRS 5558 Evaluation et Modélisation des Effets Thérapeutiques, Université Claude Bernard Lyon 1, Lyon, France; Unité de Recherche Clinique, Innovation, Pharmacologie, Centre hospitalo-universitaire de Saint-Etienne, France","¶ Membership of The Meta-Embol Group is provided in the Acknowledgments.","JCL, PM, MC, LB, CG, DVD and CC received no direct support for this study; SL received support from the Ministère de la Recherche through a Programme Hospitalier de Recherche Clinique grant in 2008 (Meta-Embol). PM and SL sit on advisory boards for Boehringer Ingelheim, BMS/Pfizer and Bayer, as well as Daichii Sankyo in the case of PM. LB has received honoraria from Sanofi-Aventis, BMS/Pfizer, Boehringer Ingelheim and Bayer. PM has received honoraria from Sanofi-Aventis, GSK, Astra Zeneca, Merck Serono, Boehringer Ingelheim and Bayer; SL has received honoraria from Sanofi-Aventis, Merck Serono, Boehringer Ingelheim and Bayer; there are no other relationships or activities that could have potentially influenced the submitted work. MC has received research funding or speaking fees from, or acted as a consultant for GSK, Bayer, Pfizer and BMS. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","2014","03","Jean-Christophe Lega","JCL",9,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
